Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

EPIDERMAL GROWTH FACTOR-UROGASTRONE --- CELLS, CULTURED --- CARTILAGE, ARTICULAR --- EPIDERMAL GROWTH FACTOR-UROGASTRONE --- CELLS, CULTURED --- CARTILAGE, ARTICULAR

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Epidermis --- Epidermal growth factor --- Growth factors --- Epidermal Growth Factor --- Cytokines --- Molecular aspects --- physiology --- Cytokines. --- Epidermal growth factor. --- Growth factors. --- Epidermal Growth Factor-Urogastrone --- Molecular aspects. --- physiology. --- Human Urinary Gastric Inhibitor --- beta-Urogastrone --- EGF --- Urogastrone --- Growth Factor, Epidermal --- Growth Factor-Urogastrone, Epidermal --- beta Urogastrone --- Epidermis - Molecular aspects --- Epidermal Growth Factor - physiology --- Cytokines - physiology

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Lung cancer is still a major cause of death globally, but the development of personalized, precision medicine has had a marked effect on treatment management and improved clinical outcomes, particularly for those with advanced stage non-small-cell lung cancer (NSCLC). EGFR mutations are the third most common mutation found in patients with advanced stage NSCLC. First-line treatment with a traditional epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is indicated for most patients, but not for patients with EGFR exon 20 insertion mutations (ex20ins). Instead, recent approvals of an EGFR ex20ins-specific TKI (mobocertinib) and a bispecific antibody (amivantamab) targeting both EGFR and mesenchymalepithelial transition factor (MET) offer the potential for improved outcomes in this patient population. Furthermore, new approaches to treatment continue to be developed and trials for new agents with greater activity against ex20ins mutations are ongoing.

Epidermal growth factor. --- Lungs --- Cancer --- Genetic aspects. --- Anthelone --- EGF (Growth factor) --- EGF-URO (Growth factor) --- EGF-Urogastrone --- Epidermal growth factor-Urogastrone --- Uroanthelone --- Uroenterone --- Growth factors

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

EPIDERMAL GROWTH FACTOR-UROGASTRONE --- ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL --- INDOMETHACIN --- THIAZINES --- ASPIRIN --- SYNOVIAL MEMBRANE --- CELLS, CULTURED --- ANALOGS AND DERIVATIVES --- EPIDERMAL GROWTH FACTOR-UROGASTRONE --- ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL --- INDOMETHACIN --- THIAZINES --- ASPIRIN --- SYNOVIAL MEMBRANE --- CELLS, CULTURED --- ANALOGS AND DERIVATIVES

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Guide to Targeted Therapies: EGFR Mutations in NSCLC is a speedy and up-to-date review, which discusses EGFR mutations, testing methods and technology, current and emerging therapies, and resources that clinicians can provide to their patients. Busy healthcare professionals who want a quick review of EGFR gene mutations as well as a summary of current therapies will benefit from this succinct guide.

Epidermal growth factor. --- Anthelone --- EGF (Growth factor) --- EGF-URO (Growth factor) --- EGF-Urogastrone --- Epidermal growth factor-Urogastrone --- Uroanthelone --- Uroenterone --- Growth factors --- Medicine. --- Oncology  . --- Pneumology. --- Medicine/Public Health, general. --- Oncology. --- Pharmacotherapy. --- Pneumology/Respiratory System. --- Tumors --- Clinical sciences --- Medical profession --- Human biology --- Life sciences --- Medical sciences --- Pathology --- Physicians --- Health Workforce --- Respiratory organs—Diseases. --- Drug therapy --- Pharmacotherapy --- Therapeutics --- Drugs --- Pharmacology